STOCK TITAN

Vera Therapeutics, Inc. - VERA STOCK NEWS

Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.

Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company committed to developing and commercializing pioneering treatments for patients with serious immunological diseases. The company's primary product candidate, atacicept, is a fusion protein designed for subcutaneous injection once weekly. Atacicept blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby inhibiting the stimulation of B cells and plasma cells that produce autoantibodies contributing to autoimmune diseases such as IgA nephropathy (IgAN) and lupus nephritis.

One of the company's significant achievements is the development of atacicept, which has shown promising results in clinical trials. The Phase 2b ORIGIN clinical trial demonstrated atacicept's potential to modify disease progression in IgAN patients, with data showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, along with stable eGFR over 72 weeks. The ongoing pivotal Phase 3 ORIGIN 3 trial aims to further evaluate atacicept's efficacy and safety in a larger cohort of IgAN patients.

Additionally, Vera is advancing MAU868, a monoclonal antibody designed to neutralize BK virus (BKV) infections, which are particularly problematic in kidney transplant patients. Vera retains global developmental and commercial rights to both atacicept and MAU868, positioning the company well in the biopharmaceutical market.

Financially, Vera reported a net loss of $28.4 million for the quarter ended March 31, 2024, with sufficient cash reserves to fund operations through the potential approval and U.S. launch of atacicept. The company has also announced various strategic partnerships and funding rounds to support its ambitious research and development goals.

Recently, Vera Therapeutics received FDA Breakthrough Therapy Designation for atacicept in IgAN, indicating the drug's potential to substantially improve kidney function compared to existing therapies. This designation expedites the development and review process, bringing hope to patients suffering from this debilitating disease.

For more information about Vera Therapeutics and its clinical trials, please visit the company's website at www.veratx.com.

Rhea-AI Summary

Vera Therapeutics has completed patient enrollment for the Phase 2b ORIGIN clinical trial of atacicept, aimed at treating IgA nephropathy (IgAN), a serious kidney disease. The trial involves 115 patients who are at high risk of disease progression despite existing treatments. Topline results are expected in Q4 2022. Atacicept is designed to reduce proteinuria, a key marker of kidney damage. This milestone comes as IgAN has no approved treatments, affecting an estimated 400,000 patients in the U.S., EU, and Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
-
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced positive interim results from a Phase 2 trial of MAU868, a first-in-class monoclonal antibody targeting BK Virus (BKV) in kidney transplant recipients. Presented at the American Transplant Congress 2022, data showed MAU868 was well tolerated and demonstrated significant antiviral activity, with 55% of patients achieving a prespecified reduction in BK plasma viral load. As there are currently no approved treatments for BKV, these results support the further development of MAU868 as a promising therapeutic option for affected patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company, has announced its participation at the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. The management team will present on June 8 at 4:00 PM ET and engage in one-on-one investor meetings. A live audio webcast will be available, with a replay accessible for 90 days via the investor calendar on the company’s website. Vera focuses on transformative treatments for serious immunological diseases, including its lead candidate, atacicept, for autoimmune disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced promising new clinical data for atacicept, its lead product candidate, during the ERA-EDTA Congress. The investigational therapy demonstrated its ability to reduce both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies, which are linked to IgA nephropathy progression. In a Phase 2a trial, atacicept showed a significant decrease in anti-Gd-IgA1 levels, with reductions of up to 39% at 72 weeks. A post-hoc analysis from a Phase 2 study indicated potential renal function improvement in systemic lupus erythematosus patients. The company is advancing atacicept through further clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.8%
Tags
-
Rhea-AI Summary

Vera Therapeutics (VERA) remains on track with its Phase 2b ORIGIN clinical trial for atacicept, with topline data anticipated in Q4 2022. A Phase 3 trial for lupus nephritis is set to begin in the second half of 2022, following positive FDA interactions. The company boasts a robust balance sheet with approximately $151 million in cash and a $45 million credit facility, expected to fund operations through Q2 2024. Despite a net loss of $17.1 million for Q1 2022, the company continues to advance its clinical pipeline and maintain strong enrollment in its studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
-
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced participation in two key conferences in May 2022. The first is the LifeSci Partners Immunology & Inflammation Symposium on May 10, from 2:30-2:55 PM ET, featuring a fireside chat format. The second is the H.C. Wainwright Global Investment Conference from May 23-26, with a presentation scheduled for May 25, 1:30-2:00 PM ET. Both events will have live audio webcasts available online. Vera focuses on transformative treatments for serious immunological diseases, including its lead candidate, atacicept.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced two significant oral presentations of clinical data for its lead candidate, atacicept, at the upcoming ERA-EDTA Congress from May 19-22, 2022, in Paris. The presentations will include results from the Phase 2a JANUS trial on IgA nephropathy and a post-hoc analysis of the APRIL-SLE study in systemic lupus erythematosus. Atacicept, a weekly subcutaneous injection, targets B-cell activity linked to autoimmune diseases and has shown promising results in clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
-
Rhea-AI Summary

Vera Therapeutics, Inc. (NASDAQ: VERA) announced that interim data from its Phase 2 trial of MAU868 versus placebo for treating BK Virus (BKV) in kidney transplant patients will be shared in a late-breaking presentation at the American Transplant Congress (ATC) 2022 on June 4, 2022. The trial aims to assess MAU868's safety and efficacy and represents a significant step in addressing BKV, a serious complication for transplant recipients. Vera holds exclusive worldwide rights for MAU868, acquired from Amplyx Pharmaceuticals, a Pfizer subsidiary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
conferences clinical trial
-
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) has appointed Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey, former president and CEO of Exelixis, brings extensive biopharmaceutical experience and expertise in drug development, regulatory processes, and commercialization. His leadership is expected to guide Vera as it transitions from late-stage clinical programs to commercialization efforts. The company focuses on innovative treatments for serious immunological diseases, including its lead candidate atacicept for IgA nephropathy and lupus nephritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
management
Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) reports significant progress in its clinical pipeline, including the Phase 2b ORIGIN trial for atacicept, expecting topline data in Q4 2022. The company strengthened its financial position with an $80.2 million equity offering and plans a Phase 3 trial for atacicept in lupus nephritis. Furthermore, the acquisition of MAU868 aims to treat BK Virus infections, with interim results expected mid-2022. Vera ended 2021 with $79.7 million in cash, showing a reduced net loss of $16.8 million for Q4 2021, compared to $42.9 million the previous year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags

FAQ

What is the current stock price of Vera Therapeutics (VERA)?

The current stock price of Vera Therapeutics (VERA) is $42.31 as of December 23, 2024.

What is the market cap of Vera Therapeutics (VERA)?

The market cap of Vera Therapeutics (VERA) is approximately 2.7B.

What is Vera Therapeutics?

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

What is atacicept?

Atacicept is a fusion protein developed by Vera Therapeutics for the treatment of autoimmune diseases, administered as a subcutaneous injection once weekly.

What is the ORIGIN clinical trial?

The ORIGIN clinical trial is a series of studies evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN).

What is IgA nephropathy (IgAN)?

IgAN, also known as Berger’s disease, is a serious autoimmune disease of the kidney characterized by the production of immunogenic Gd-IgA1 and progressive kidney damage.

What is MAU868?

MAU868 is a monoclonal antibody developed by Vera Therapeutics to neutralize BK virus (BKV) infections, particularly in kidney transplant patients.

What recent achievements has Vera Therapeutics reported?

Vera recently announced positive 72-week data from its Phase 2b ORIGIN trial of atacicept in IgAN and received FDA Breakthrough Therapy Designation for atacicept.

How is atacicept administered?

Atacicept is administered as a subcutaneous injection once weekly.

What are the financial highlights of Vera Therapeutics?

For the quarter ended March 31, 2024, Vera reported a net loss of $28.4 million, with cash reserves to fund operations through the approval and U.S. launch of atacicept.

Who are Vera’s strategic partners?

Vera has various strategic partnerships and funding rounds to support its research and development, including J.P. Morgan, TD Cowen, and Evercore ISI.

Where can I find more information about Vera Therapeutics?

For more information, please visit the company's website at www.veratx.com.

Vera Therapeutics, Inc.

Nasdaq:VERA

VERA Rankings

VERA Stock Data

2.69B
58.22M
6.83%
95.11%
10.34%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE